» Articles » PMID: 14697644

Cytogenetic and Fluorescence in Situ Hybridization Studies in 60 Patients with Multiple Myeloma and Plasma Cell Leukemia

Overview
Date 2003 Dec 31
PMID 14697644
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

We report cytogenetic results in a series of 60 patients affected with multiple myeloma (MM) and plasma cell leukemia (PCL) and compare the results with those previously reported. In our series, a total of 41% of MM patients and 71% of PCL patients displayed chromosome abnormalities. To evaluate the clinical value of monosomy 18, we obtained fluorescence in situ hybridization results (using centromeric probe for chromosome 18) of 22 MM patients who displayed a normal karyotype. Monosomy 18 was present in 3 of 22 patients (14%). Using conventional cytogenetics, we detected monosomy 18 in one patient affected with PCL. Two of four cases with monosomy 18 followed an aggressive course, with overall survival of 1 and 9 months. The remaining two are in follow-up and remain stable. The association of monosomy 18 with IgA subtype predominance and poor prognosis was not observed in this series of MMs and PCLs. Although these results do not confirm our previous hypothesis, further observations of this group of patients (with monosomy 18) regarding malignant transformation is warranted.

Citing Articles

Profile of Chromosomal Alterations, Chromosomal Instability and Clonal Heterogeneity in Colombian Farmers Exposed to Pesticides.

Melendez-Florez M, Valbuena D, Cepeda S, Rangel N, Forero-Castro M, Martinez-Aguero M Front Genet. 2022; 13:820209.

PMID: 35281828 PMC: 8908452. DOI: 10.3389/fgene.2022.820209.


Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.

Hamdaoui H, Benlarroubia O, Ait Boujmia O, Mossafa H, Ouldim K, Belkhayat A Mol Genet Genomic Med. 2020; 8(9):e1363.

PMID: 32573970 PMC: 7507047. DOI: 10.1002/mgg3.1363.


Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.

Zatula A, Dikic A, Mulder C, Sharma A, Vagbo C, Sousa M Oncotarget. 2016; 8(12):19427-19442.

PMID: 28038447 PMC: 5386695. DOI: 10.18632/oncotarget.14294.


Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Durak B, Akay O, Sungar G, Bademci G, Aslan V, Caferler J Turk J Haematol. 2014; 29(2):135-42.

PMID: 24744644 PMC: 3986951. DOI: 10.5152/tjh.2011.42.


Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Di Martino M, Leone E, Amodio N, Foresta U, Lionetti M, Pitari M Clin Cancer Res. 2012; 18(22):6260-70.

PMID: 23035210 PMC: 4453928. DOI: 10.1158/1078-0432.CCR-12-1708.